Oppenheimer Asset Management Inc. Grows Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Oppenheimer Asset Management Inc. raised its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 16.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,213 shares of the company’s stock after purchasing an additional 1,747 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in IDEAYA Biosciences were worth $429,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IDYA. Charles Schwab Investment Management Inc. lifted its stake in shares of IDEAYA Biosciences by 13.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 496,456 shares of the company’s stock valued at $17,664,000 after buying an additional 59,100 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its position in shares of IDEAYA Biosciences by 93.2% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 61,226 shares of the company’s stock valued at $2,178,000 after acquiring an additional 29,536 shares in the last quarter. First Light Asset Management LLC bought a new position in shares of IDEAYA Biosciences in the fourth quarter worth about $12,299,000. Superstring Capital Management LP purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter worth about $8,941,000. Finally, Vanguard Group Inc. grew its position in shares of IDEAYA Biosciences by 17.0% during the fourth quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock worth $123,668,000 after purchasing an additional 504,275 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on IDYA shares. Stifel Nicolaus upped their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Wedbush reiterated an “outperform” rating and issued a $54.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, August 7th. BTIG Research boosted their price target on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. JPMorgan Chase & Co. cut their price objective on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Citigroup decreased their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Twelve equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $56.20.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $35.00 on Friday. The company has a market cap of $2.65 billion, a PE ratio of -17.41 and a beta of 0.84. IDEAYA Biosciences, Inc. has a 1 year low of $23.41 and a 1 year high of $47.74. The stock’s 50 day simple moving average is $38.92 and its two-hundred day simple moving average is $39.75.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.52%. During the same period in the previous year, the business posted ($0.50) EPS. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.